| Bioactivity | Aurora Kinases-IN-4 (Compound 11c) is a covalent and ATP competitive aurora kinase A inhibitor (IC50: 1.7 nM). Aurora Kinases-IN-4 inhibits cell proliferation in SJSA-1, MDA-MB-231, A54, HeLa cells with IC50s of 4.27, 1.54, 3.08, 6.99 μM. Aurora Kinases-IN-4 can be used for research of triple negative breast cancer (TNBC)[1]. |
| Name | Aurora Kinases-IN-4 |
| CAS | 2877011-84-0 |
| Formula | C26H28N8O |
| Molar Mass | 468.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang B, et al. Discovery of a first-in-class Aurora A covalent inhibitor for the treatment of triple negative breast cancer. Eur J Med Chem. 2023 Aug 5;256:115457. |
Aurora Kinases-IN-4
CAS: 2877011-84-0 F: C26H28N8O W: 468.55
Aurora Kinases-IN-4 (Compound 11c) is a covalent and ATP competitive aurora kinase A inhibitor (IC50: 1.7 nM). Aurora Ki
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.